Trial reportDrug design, development and therapy2025
Effect of Subanesthetic Dose of Esketamine on Liver Function Following Microvascular Reconstruction for Head and Neck Cancer: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Esketamine/Ketamine: Dual-Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Abnormal liver function is common post-surgery and is linked to poor prognosis. We investigated whether intraoperative subanesthetic esketamine could improve postoperative liver function and recovery quality by reducing surgery-induced inflammation in patients with head and neck squamous cell carcinoma (HNSCC). Patients and methods: In this randomized controlled trial, 172 hNSCC patients were randomly assigned to receive esketamine or saline intravenously. The primary outcome was serum alanine aminotransferase (ALT) on postoperative day (POD) 1. Secondary outcomes included aspartate aminotransferase (AST), abnormal liver function event (ALFE), inflammatory markers (serum C-reactive protein [CRP], white blood cell [WBC] count, neutrophil percentage (NE%) and the neutrophil-to-lymphocyte ratio [NLR]) on POD1, and recovery quality measured by the quality of recovery (QoR)-40 questionnaire on POD1 and POD7. Results: The esketamine group showed a lower mean [standard deviation, SD] ALT (27.72 [13.04] vs 50.74 [20.14] U/L; Conclusion: Subanesthetic esketamine improved postoperative liver function and recovery quality in HNSCC patients, possibly by reducing surgery-induced inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.